Bank of America just raised its EUR/USD forecast
Director Timothy S. Cabral of Doximity , Inc. (NYSE:DOCS), a $12.4 billion healthcare technology company with impressive 90% gross margins, sold 20,000 shares of Class A Common Stock on August 15, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sales totaled $1.27 million, with prices ranging from $63.682 to $64.1889. According to InvestingPro analysis, the stock is currently trading above its Fair Value, after gaining over 82% in the past year.
Cabral sold 16,200 shares at a weighted-average price of $63.682, for a total of $1,031,650. Additionally, Cabral sold 3,800 shares at a weighted-average price of $64.1889, totaling $243,918. The sales were executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on February 13, 2025. For comprehensive insider trading analysis and 15 additional key insights about DOCS, unlock InvestingPro’s exclusive research report.
On the same day, Cabral exercised options to acquire 20,000 shares of Class A Common Stock, and converted 20,000 shares of Class B Common Stock into Class A Common Stock. The company maintains a strong financial position with a current ratio of 6.47, indicating robust liquidity to meet short-term obligations.
In other recent news, Doximity Inc. reported impressive financial results for the first quarter of fiscal year 2026. The company exceeded Wall Street’s expectations by posting earnings per share of $0.36, surpassing the projected $0.30 by 20%. Additionally, Doximity achieved a revenue of $145.9 million, which was 4.64% higher than the anticipated $139.43 million. In a separate development, Piper Sandler increased its price target for Doximity to $69, up from $65, while maintaining an Overweight rating. The research firm attributed this adjustment to Doximity’s advancements in AI and workflow product innovation. Piper Sandler noted that the utilization of the Doximity app has reached unprecedented levels, driven by features like Doximity AI Scribe and Doximity GPT. These recent developments highlight Doximity’s strong performance and strategic innovation in the healthcare technology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.